A concentrated form of a kratom-derived compound called 7-hydroxymitragynine (7-OH) is emerging as a serious public health threat, with confirmed overdose deaths and poison control calls surging across the United States. Unlike traditional kratom leaf products sold in health stores, concentrated 7-OH is being manufactured and sold in gas stations, smoke shops, and online as gummies, tablets, drinks, and vape products—often with no dosing guidance or safety warnings .

How Potent Is 7-OH Compared to Other Opioids?

Research from Johns Hopkins University School of Medicine shows that 7-OH binds to mu-opioid receptors with 14 to 22 times the affinity of morphine, making it significantly more potent than the primary alkaloid in traditional kratom . To put this in perspective, a 2019 study published in Addiction Biology found that 7-OH—but not regular kratom—substituted for morphine in animal models, indicating serious abuse liability. The study also raised concerns about gateway effects, showing that exposure to 7-OH subsequently increased morphine self-administration .

Dr. Christopher McCurdy, a professor of medicinal chemistry at the University of Florida College of Pharmacy, has compared the marketing of concentrated 7-OH products to the early promotion of OxyContin in the 1990s. His laboratory research has demonstrated that 7-OH is as highly addictive as prescription opioids and that its respiratory depressive effects can be reversed with naloxone (Narcan)—a hallmark characteristic of opioid agonism .

What Forms Are 7-OH Products Taking, and Where Are They Sold?

Concentrated 7-OH products are widely available across the United States in forms that are virtually indistinguishable from over-the-counter supplements or candy. The Los Angeles County Department of Public Health noted in a September 2025 health alert that these products are sold in gas stations, smoke shops, and online venues, often labeled with vague terms like "plant alkaloids" or simply "alkaloid" rather than clearly identifying the active ingredient .

Tablets: Typically ranging from 5 milligrams to 22 milligrams per tablet, with purple tablets commonly containing 20–22 milligrams and green tablets containing 5–10 milligrams. Many are scored for splitting.
Gummies and candy: Designed with appealing colors and flavors that may attract younger consumers. Colorado enacted legislation specifically prohibiting kratom products from being sold as candy or in forms that appeal to children.
Drink shots and mixes: Pocket-sized liquid vials marketed alongside energy drinks and supplements.
Vape products: Offering nearly immediate onset of effects through inhalation.

In July 2025, the Food and Drug Administration (FDA) issued warning letters to seven companies for illegally marketing concentrated 7-OH products as dietary supplements, foods, or unapproved drugs. The agency emphasized that 7-OH cannot be lawfully sold as a dietary supplement and cannot be legally added to conventional foods. There are no FDA-approved drug products containing 7-OH .

How Many Deaths and Emergency Visits Have Been Linked to 7-OH?

The public health data surrounding concentrated 7-OH products has escalated rapidly. In Los Angeles County, the County Medical Examiner identified three fatal overdoses in residents aged 18 to 40 in September 2025. All three individuals were described as otherwise healthy, with no other substances identified as substantively contributing to their deaths. Alcohol was present in all cases, and 7-OH was identified as the primary cause of death .

In Texas, the Texas Poison Center Network received 192 reports of kratom and 7-OH exposures by late August 2025, compared to 107 for all of 2024 and 122 for all of 2023. Of 19 patients exposed specifically to concentrated 7-OH products, 11 required treatment at healthcare facilities . Pennsylvania reported that 14 patients required mechanical ventilation due to severe respiratory distress following 7-OH exposure, while Washington State saw poison center kratom exposures surge to 1,800 by early August 2025, with approximately one-third of calls specifically involving 7-OH extracts .

What Makes 7-OH Withdrawal Different From Other Opioids?

One critical challenge for addiction professionals is that 7-OH withdrawal can last significantly longer than traditional opioid withdrawal—potentially up to three months—complicating treatment and increasing relapse risk . This extended withdrawal timeline means patients require longer-term medical support and monitoring, which has implications for treatment planning and resource allocation in addiction recovery programs.

Steps for Addiction Professionals to Identify and Respond to 7-OH Use

Screen for kratom and alkaloid products: Ask patients directly about use of kratom, "plant alkaloids," or concentrated alkaloid products, especially if they report opioid-like effects or respiratory symptoms.
Recognize the distinction: Understand that concentrated 7-OH products are dramatically different from traditional whole-leaf kratom, which contains only trace amounts (typically below 2%) of 7-OH.
Plan for extended withdrawal management: If 7-OH use is identified, prepare patients and families for withdrawal lasting up to three months and ensure access to medical supervision and counseling throughout this extended period.
Monitor for respiratory depression: Be alert to signs of respiratory distress, especially when 7-OH is combined with alcohol or other sedatives, and ensure naloxone is available and that patients know how to use it.

The FDA recommended Schedule I classification for concentrated 7-OH products in July 2025, and the Drug Enforcement Administration (DEA) is currently reviewing whether to proceed with scheduling—a decision that could come in 2026 . This regulatory action reflects the growing recognition of 7-OH as a serious public health threat requiring controlled substance status.

For addiction professionals and the public, the key takeaway is clear: concentrated 7-OH is not the same as traditional kratom. It is a potent opioid-like compound being sold in deceptive packaging without adequate warnings, and it carries significant risks of addiction, overdose, and death. Awareness and early identification are critical steps in protecting vulnerable populations from this emerging threat.